Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Election campaign

    - PMLiVE

    Novo Nordisk agrees to lower certain drug prices in the US

    The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

    - PMLiVE

    Lilly announces agreement with US government to lower patient costs

    The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

    - PMLiVE

    NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

    More than 11,000 people are diagnosed with head and neck cancers every year in England

    Navigating NHS Market Access: Policy Change and Opportunity in England With Sarah Everest Ford

    Navigating NHS Market Access: Policy Change and Opportunity in England

    With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...

    Petauri Evidence

    - PMLiVE

    Digital Transformation in the NHS’s 10-Year Plan: Techno-Optimism and the Limits of Efficiency

    Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the National Health Service (NHS) in England’s newly unveiled 10-year plan through the...

    Petauri Evidence

    - PMLiVE

    Live Q&A: Beyond NHS England – Navigating changes at NHSE and DHSC

    What impact can we expect from the abolition of NHS England (NHSE) and changes at the Department of Health and Social Care (DHSC)? What do these changes mean for your...

    Petauri Evidence

    - PMLiVE

    Live Q&A: Beyond NHS England – Restructuring and its implications for Pharma and Medtech

    What does the abolition of NHS England mean for your market access and NHS Engagement strategy? How will the changes at national and integrated care board (ICB) level impact launch...

    Petauri Evidence

    - PMLiVE

    The abolition of NHS England: Navigating NHS restructuring and its impact on the pharmaceutical industry

    Last week Prime Minister Sir Keir Starmer announced the abolition of NHS England to "cut bureaucracy" and bring management of the health service "back into democratic control". This significant change...

    Petauri Evidence

    - PMLiVE

    Prime minister unveils UK government’s plans to abolish NHS England

    The move aims to cut waiting times and free up money for front-line services

    - PMLiVE

    NHS England appoints Sir James Mackey as CEO

    Mackey is currently serving as chief executive of Newcastle Hospitals NHS Foundation Trust

    - PMLiVE

    NHS England begins newborn screening programme to identify rare genetic conditions

    The Generation Study is aiming to screen 100,000 newborns for more than 200 diseases

    - PMLiVE

    What is willingness to pay? – Comparing price testing methodologies

    Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...

    Petauri Evidence

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links